| [1] |
. Drug Alcohol Depend，2014，143：11-21.
|
| [2] |
Won S，Hong RA，Shohet RV，et al. Methamphetamine-associated cardiomyopathy［J］. Clin Cardiol，2013，36（12）：737-742.
|
| [3] |
Kevil CG，Goeders NE，Woolard MD，et al. Methamphetamine use and cardiovascular disease［J］. Arterioscler Thromb Vasc Biol，2019，39（9）：1739-1746.
|
| [4] |
Wodarz N，Krampe-Scheidler A，Christ M，et al. Evidence-based guidelines for the pharmacological management of acute methamphetamine-related disorders and toxicity［J］. Pharmacopsychiatry，2017，50（3）：87-95.
|
| [5] |
Suetani S，Reddan J，Anderson C. Methamphetamine and psychiatry：a story of the colourless substance of abuse［J］. Australas Psychiatry，2017，25（3）：254-256.
|
| [6] |
Paratz ED，Cunningham NJ，MacIsaac AI. The cardiac complications of methamphetamines［J］. Heart Lung Circ，2016，25（4）：325-332.
|
| [7] |
Cao YY，Pu XP. Biomarkers of methamphetamine addiction and its measurements technique evolvement［J］. Chin J New Drugs（中国新药杂志），2019，28（1）：34-39.
|
| [8] |
Mendelson J，Baggott MJ，Flower K，et al. Developing biomarkers for methamphetamine addiction［J］. Curr Neuropharmacol，2011，9（1）：100-103.
|
| [9] |
Zaitsu K，Miyawaki I，Bando K，et al. Metabolic profiling of urine and blood plasma in rat models of drug addiction on the basis of morphine，methamphetamine，and cocaine-induced conditioned place preference［J］. Anal Bioanal Chem，2014，406（5）：1339-1354.
|
| [10] |
Choi B，Kim SP，Hwang S，et al. Metabolic characterization in urine and hair from a rat model of methamphetamine self-administration using LC-QTOF-MS-based metabolomics［J］. Metabolomics，2017，13（10）：1-17.
|
| [11] |
Zheng T，Liu LS，Shi J，et al. The metabolic impact of methamphetamine on the systemic metabolism of rats and potential markers of methamphetamine abuse［J］. Mol Biosyst，2014，10（7）：1968-1977.
|
| [12] |
Zhao Y，Zhang K，Jiang HF，et al. Decreased expression of plasma microRNA in patients with methamphetamine （MA） use disorder［J］. J Neuroimmune Pharmacol，2016，11（3）：542-548.
|
| [13] |
Alasmari F，Alsanea S，Masood A，et al. Serum proteomic profiling of patients with amphetamine use disorder［J］. Drug Alcohol Depend，2020，214：108157.
|
| [14] |
Shi WL，Zhao X，Liu ZM，et al. Serum proteomics of methamphetamine addicts and up-regulation of complement factor H related to methamphetamine addiction［J］. Neurosci Lett，2012，525（1）：23-28.
|
| [15] |
Lin M，Xu JM，Liu X，et al. Metabolomics profiling of methamphetamine addicted human serum and three rat brain areas［J］. RSC Adv，2019，9（70）：41107-41119.
|
| [16] |
Bai J，Wang MX，Chowbay B，et al. Metabolic profiling of HepG2 cells incubated with S （?） and R（+） enantiomers of anti-coagulating drug warfarin［J］. Metabolomics，2011，7（3）：353-362.
|
| [17] |
Cao B，Li MJ，Zha WB，et al. Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells［J］. Metabolomics，2013，9（5）：960-973.
|
| [18] |
Ouattara DA，Prot JM，Bunescu A，et al. Metabolomics-on-a-chip and metabolic flux analysis for label-free modeling of the internal metabolism of HepG2/C3A cells［J］. Mol Biosyst，2012，8（7）：1908-1920.
|
| [19] |
Lin SH，Yang Z，Liu HD，et al. Metabolomic analysis of liver and skeletal muscle tissues in C57BL/6J and DBA/2J mice exposed to 2，3，7，8-tetrachlorodibenzo-p-dioxin［J］. Mol Biosyst，2011，7（6）：1956-1965.
|
| [20] |
Wikoff WR，Gangoiti JA，Barshop BA，et al. Metabolomics identifies perturbations in human disorders of propionate metabolism［J］. Clin Chem，2007，53（12）：2169-2176.
|
| [21] |
Xue RY，Lin ZX，Deng CH，et al. A serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry［J］. Rapid Commun Mass Spectrom，2008，22（19）：3061-3068.
|
| [22] |
Bogdanov M，Matson WR，Wang L，et al. Metabolomic profiling to develop blood biomarkers for Parkinson''s disease［J］. Brain，2008，131（Pt 2）：389-396.
|
| [23] |
Nicholson JK，Connelly J，Lindon JC，et al. Metabonomics：a platform for studying drug toxicity and gene function［J］. Nat Rev Drug Discov，2002，1（2）：153-161.
|
| [24] |
H?fner H，Riecher-R?ssler A，An der Heiden WA，et al. Generating and testing a causal explanation of the gender difference in age at first onset of schizophrenia［J］. Psychol Med，1993，23（4）：925-940.
|
| [25] |
Hallonquist JD，Seeman MV，Lang M，et al. Variation in symptom severity over the menstrual cycle of schizophrenics［J］. Biol Psychiatry，1993，33（3）：207-209.
|
| [26] |
Cai HL，Li HD，Yan XZ，et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-na?ve schizophrenia patients after treatment with risperidone［J］. J Proteome Res，2012，11（8）：4338-4350.
|
| [27] |
Hermens DF，Lubman DI，Ward PB，et al. Amphetamine psychosis：a model for studying the onset and course of psychosis［J］. Med J Aust，2009，190（S4）：S22-S25.
|
| [28] |
Tirodkar TS，Voelkel-Johnson C. Sphingolipids in apoptosis［J］. Exp Oncol，2012，34（3）：231-242.
|
| [29] |
Law SH，Chan ML，Marathe GK，et al. An updated review of lysophosphatidylcholine metabolism in human diseases［J］. Int J Mol Sci，2019，20（5）：1149.
|
| [30] |
Tian ZS. Effect of platelet activating factor and its receptor-dependent and receptor-independent pathway in the demyelination of central nervous system（血小板激活因子与其受体依赖及非受体依赖信号通路在中枢神经系统脱髓鞘病变中的作用研究）［D］. Changchun：Jilin University，2020.
|
下载:
